BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 37661807)

  • 1. Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others.
    Li H; Argani P; Halper-Stromberg E; Lotan TL; Merino MJ; Reuter VE; Matoso A
    Am J Surg Pathol; 2023 Nov; 47(11):1267-1273. PubMed ID: 37661807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
    Shah RB; Stohr BA; Tu ZJ; Gao Y; Przybycin CG; Nguyen J; Cox RM; Rashid-Kolvear F; Weindel MD; Farkas DH; Trpkov K; McKenney JK
    Am J Surg Pathol; 2020 May; 44(5):571-581. PubMed ID: 31850909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal Cell Carcinoma With Fibromyomatous Stroma-The Whole Story.
    Shah RB
    Adv Anat Pathol; 2022 May; 29(3):168-177. PubMed ID: 35249990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biallelic ELOC-Inactivated Renal Cell Carcinoma: Molecular Features Supporting Classification as a Distinct Entity.
    Batavia AA; Rutishauser D; Sobottka B; Schraml P; Beerenwinkel N; Moch H
    Mod Pathol; 2023 Aug; 36(8):100194. PubMed ID: 37088333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TSC/MTOR mutated renal cell carcinoma with leiomyomatous stroma is a distinct entity: a comprehensive study of 12 cases.
    Tjota MY; Sharma A; Wanjari P; Fitzpatrick C; Segal J; Antic T
    Hum Pathol; 2023 Apr; 134():124-133. PubMed ID: 36592877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of clinicopathological and molecular features of ELOC(TCEB1)-mutant renal cell carcinoma.
    Wang Y; Zhao P; Wang L; Wang J; Ji X; Li Y; Shi H; Li Y; Zhang W; Jiang Y
    Pathol Res Pract; 2022 Jul; 235():153960. PubMed ID: 35653922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms.
    Salles DC; Asrani K; Woo J; Vidotto T; Liu HB; Vidal I; Matoso A; Netto GJ; Argani P; Lotan TL
    J Pathol; 2022 Jun; 257(2):158-171. PubMed ID: 35072947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New insights in the new WHO classification of adult renal tumors.
    Hes O; Michalová K; Pivovarčíková K
    Cesk Patol; 2022; 67(4):187-191. PubMed ID: 36513503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatic Mutations of TSC2 or MTOR Characterize a Morphologically Distinct Subset of Sporadic Renal Cell Carcinoma With Eosinophilic and Vacuolated Cytoplasm.
    Chen YB; Mirsadraei L; Jayakumaran G; Al-Ahmadie HA; Fine SW; Gopalan A; Sirintrapun SJ; Tickoo SK; Reuter VE
    Am J Surg Pathol; 2019 Jan; 43(1):121-131. PubMed ID: 30303819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eosinophilic Renal Cell Tumors With a TSC and MTOR Gene Mutations Are Morphologically and Immunohistochemically Heterogenous: Clinicopathologic and Molecular Study.
    Tjota M; Chen H; Parilla M; Wanjari P; Segal J; Antic T
    Am J Surg Pathol; 2020 Jul; 44(7):943-954. PubMed ID: 32091432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutated ASXL1 upregulates mTOR expression in renal cell carcinoma with fibromyomatous stroma.
    Liu Y; Zhou L; Xu H; Gu Y; Dong L; Yang X; Wang C
    Virchows Arch; 2023 Dec; ():. PubMed ID: 38102390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TCEB1-mutated renal cell carcinoma: a distinct genomic and morphological subtype.
    Hakimi AA; Tickoo SK; Jacobsen A; Sarungbam J; Sfakianos JP; Sato Y; Morikawa T; Kume H; Fukayama M; Homma Y; Chen YB; Sankin A; Mano R; Coleman JA; Russo P; Ogawa S; Sander C; Hsieh JJ; Reuter VE
    Mod Pathol; 2015 Jun; 28(6):845-853. PubMed ID: 25676555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study.
    Tjota MY; Wanjari P; Segal J; Antic T
    Hum Pathol; 2021 Sep; 115():84-95. PubMed ID: 33352195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TSC/MTOR -associated Eosinophilic Renal Tumors Exhibit a Heterogeneous Clinicopathologic Spectrum : A Targeted Next-generation Sequencing and Gene Expression Profiling Study.
    Xia QY; Wang XT; Zhao M; He HY; Fang R; Ye SB; Li R; Wang X; Zhang RS; Lu ZF; Ma HH; Wang ZY; Rao Q
    Am J Surg Pathol; 2022 Nov; 46(11):1562-1576. PubMed ID: 35980750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal Cell Carcinoma Associated With TSC/MTOR Genomic Alterations: An Update on its Expanding Spectrum and an Approach to Clinicopathologic Work-up.
    Shah RB; Mehra R
    Adv Anat Pathol; 2024 Mar; 31(2):105-117. PubMed ID: 37899532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GATA3 as a valuable marker to distinguish clear cell papillary renal cell carcinomas from morphologic mimics.
    Mantilla JG; Antic T; Tretiakova M
    Hum Pathol; 2017 Aug; 66():152-158. PubMed ID: 28705707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal Cell Carcinoma in Tuberous Sclerosis Complex.
    Henske EP; Cornejo KM; Wu CL
    Genes (Basel); 2021 Oct; 12(10):. PubMed ID: 34680979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multilocular cystic renal cell carcinoma: similarities and differences in immunoprofile compared with clear cell renal cell carcinoma.
    Williamson SR; Halat S; Eble JN; Grignon DJ; Lopez-Beltran A; Montironi R; Tan PH; Wang M; Zhang S; Maclennan GT; Baldridge LA; Cheng L
    Am J Surg Pathol; 2012 Oct; 36(10):1425-33. PubMed ID: 22982885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncocytic renal neoplasms with diffuse keratin 7 immunohistochemistry harbor frequent alterations in the mammalian target of rapamycin pathway.
    Mohanty SK; Satapathy A; Aggarwal A; Mishra SK; Sampat NY; Sharma S; Williamson SR
    Mod Pathol; 2022 Mar; 35(3):361-375. PubMed ID: 34802045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Oncocytoid Renal Cell Carcinomas After Neuroblastoma" Represent TSC -mutated Eosinophilic Solid and Cystic Renal Cell Carcinomas : Association With Prior Childhood Malignancy and Multifocality With Therapeutic Implications.
    Argani P; Medeiros LJ; Matoso A; Baraban E; Lotan T; Pawel BR; McKenney JK; Mehra R; Falzarano SM; Pallavajjalla A; Lin MT; Patel S; Rawwas J; Bendel AE; Gagan J; Palsgrove DN
    Am J Surg Pathol; 2023 Dec; 47(12):1335-1348. PubMed ID: 37522346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.